PREDICTIVE FACTORS FOR HEALTH-RELATED QUALITY OF LIFE IN TYPE 2 DIABETES PATIENTS

Authors

  • Elena-Daniela GRIGORESCU Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Cristina-Mihaela LĂCĂTUȘU Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Georgiana-Diana CAZAC Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Alina ONOFRIESCU Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Mariana FLORIA “Sf. Spiridon” County Clinical Emergency Hospital, Iasi, Romania
  • Ioana CREȚU “Crețu R. Ioana” Medical Practice, Iasi, Romania
  • B. M. MIHAI Grigore T. Popa” University of Medicine and Pharmacy Iasi

Abstract

Aims: Diabetes-related characteristics and associated chronic conditions are said to influence the health-related quality of life (QoL) of patients with type 2 diabetes mellitus (T2DM). This study assessed the relationships between QoL, demographic, and disease-related variables in T2DM patients without established atherosclerotic disease. Materials and methods: This post hoc analysis included outpatient data from a cross-sectional study. Descriptive and inferential statistics were used to examine patient characteristics in relation to QoL scores and identify predictive factors for physical and mental health perceptions. QoL was evaluated with the 36-item Short Form Health Survey (SF-36) questionnaire. Results: The 138 T2DM patients enrolled were 49.3% men, 57.86 ± 8.82 years old, with T2DM for 1 to 21 years, without optimal glycemic control under oral glucose-lowering drugs (median HbA1c7.8%). Mean physical and mental component summary scores (PCS, MCS) were 50.44 ± 16.22 and 47.78 ± 12.10, respectively. The lowest SF-36 scores were reported for physical functioning and vitality, and the highest for bodily pain. Women had significantly lower PCS scores compared to men (46.85 vs. 54.03, p = 0.01). The diastolic index E/e’, CHA2DS2-VASc score and diabetes duration predicted lower PCS (p ≤ 0.01), while the impact of age, glycemic control, neuropathy, diastolic dysfunction, and comorbidities on QoL was non-significant. The diastolic index E/e’, CHA2DS2-VASc score and diabetes duration predicted lower PCS (p ≤ 0.01). Conclusions: These results provide a nuanced view of what is clearly a complex set of relationships. Further longitudinal studies are necessary to ascertain the effects of these variables on the quality of life of T2DM patients.

Author Biographies

  • Elena-Daniela GRIGORESCU, Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Medical Specialties (II)
    “Sf. Spiridon” County Clinical Emergency Hospital, Iasi, Romania
    Clinical Center of Diabetes, Nutrition and Metabolic Diseases

  • Cristina-Mihaela LĂCĂTUȘU, Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Medical Specialties (II)
    “Sf. Spiridon” County Clinical Emergency Hospital, Iasi, Romania
    Clinical Center of Diabetes, Nutrition and Metabolic Diseases

  • Georgiana-Diana CAZAC, Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Medical Specialties (II)
    “Sf. Spiridon” County Clinical Emergency Hospital, Iasi, Romania
    Clinical Center of Diabetes, Nutrition and Metabolic Diseases

  • Alina ONOFRIESCU, Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Medical Specialties (II)
    “Sf. Spiridon” County Clinical Emergency Hospital, Iasi, Romania
    Clinical Center of Diabetes, Nutrition and Metabolic Diseases

  • Mariana FLORIA, “Sf. Spiridon” County Clinical Emergency Hospital, Iasi, Romania

    Clinical Center of Diabetes, Nutrition and Metabolic Diseases
    Internal Medicine

  • B. M. MIHAI, Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Medical Specialties (II)
    “Sf. Spiridon” County Clinical Emergency Hospital, Iasi, Romania
    Clinical Center of Diabetes, Nutrition and Metabolic Diseases

References

1. Mohammed MA, Moles RJ, Harrison J, Chen TF. Health Outcomes and Quality of Life. Encyclopedia of Pharmacy Practice and Clinical Pharmacy; Baha, Z-U-D, Ed.; Elsevier: Amsterdam, The Netherlands, 2019; 3A: 59-72.
2. ICHOM Diabetes in Adults Working Group, Type 1 and Type 2 Diabetes in Adults, November 2018, Data Collection Reference Guide. Version 1.0.0 Revised February 28th, 2019. Available online: https://ichom.org/files/medical-conditions/diabetes-in-adults/dia-reference-guide.pdf (accessed on 13 June 2024).
3. Speight J, Holmes-Truscott E, Hendrieckx C, Skovlund S, Cooke D. Assessing the impact of diabetes on quality of life: What have the past 25 years taught us? Diabet Med 2020; 37: 483-492.
4. Young-Hyman D, de Groot M, Hill-Briggs F, Gonzalez JS, Hood K, Peyrot M. Psychosocial Care for People with Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016; 39: 2126-2140.
5. American Diabetes Association. 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes-2024. Diabetes Care 2024; 47(Suppl.1): S77-S110.
6. Ware J, Kosinski M, Bjorner J, Turner-Bowker D, Gandek B, Maruish M. Development. User’s Man-ual for the SF-36v2® Health Survey. Quality Metric Incorporated: Lincoln, RI, USA, 2007.
7. Trikkalinou A, Papazafiropoulou AK, Melidonis A. Type 2 diabetes and quality of life. World J Diabetes 2017; 8(4):120.
8. Emad-Eldin M, Balata GF, Elshorbagy EA, Hamed MS, Attia MS. Insulin therapy in type 2 diabetes: Insights into clinical efficacy, patient-reported outcomes, and adherence challenges. World J Diabetes 2024; 15(5): 828-852.
9. Grigorescu E-D, et al Self-reported satisfaction to treatment, quality of life and general health of type 2 diabetes patients with inadequate glycemic control from north-eastern Romania. Int J Environ Res Public Health 2021; 18(6): 3249.
10. Grigorescu E-D, et al Effects of incretin-based treatment on the diastolic (dys)function in patients with uncontrolled type 2 diabetes mellitus: A prospective study with 1-year follow-up. Diagnostics 2023; 13(17): 2817.
11. Balta A, et al Broad electrocardiogram syndromes spectrum: From common emergencies to particular electrical heart disorders. J Pers Med 2022; 12(11): 1754.
12. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. Chest 2010; 137(2): 263-272.
13. Lionte C, Sorodoc V, Tuchilus C, Cimpoiesu D, Jaba E. Biomarkers, lactate, and clinical scores as outcome predictors in systemic poisons exposures. Hum Exp Toxicol 2017; 36(7): 651-662.
14. Jafari A, Moshki M, Ghelichi-Ghojogh M, Nejatian M. Role of diabetes health literacy, psychological status, self-care behaviors, and life satisfaction in predicting quality of life in type 2 diabetes. Scientific Reports 2024; 14(1).
15. Pérez Hernández MF, et al Electroacupuncture efficacy in diabetic polyneuropathy: Study protocol for a double-blinded randomized controlled Multicenter Clinical Trial. BMC Complement Med Ther 2024; 24(1): 90.
16. Holland-Carter L, et al Impact on psychosocial outcomes of a nationally available weight management program tailored for individuals with type 2 diabetes: Results of a randomized controlled trial. J Diabetes Complications 2017; 31(5): 891-897.
17. Bjorner JB, Lyng Wolden M, Gundgaard J, Miller KA. Benchmarks for interpretation of score differ-ences on the SF-36 health survey for patients with diabetes. Value in Health 2013; 16(6): 993-1000.
18. Grigorescu E-D, et al The inflammatory marker HSCRP as a predictor of increased insulin resistance in type 2 diabetics without atherosclerotic manifestations. Rev Chim 2019; 70(5): 1791-1794.
19. Werkman NC, et al Disease severity-based subgrouping of type 2 diabetes does not parallel differences in quality of life: The Maastricht Study. Diabetologia 2024; 67(4): 690-702.
20. Mardare I, Furtunescu FL, Bratu EC. Measuring health related quality of life - methods and tools. Acta Medica Transilvanica 2019; 24(2): 6-8.
21. Papadopoulos AA, Kontodimopoulos N, Frydas A, Ikonomakis E, Niakas D. Predictors of health-related quality of life in type II diabetic patients in Greece. BMC Public Health. 2007; 7: 186.
22. Marcos-Delgado A, et al Health-related quality of life in individuals with metabolic syndrome: A cross-sectional study. Semergen 2020; 46(8): 524-537.
23. Rani M, Kumar R, Krishan P. Metabolic correlates of health-related quality of life in patients with type 2 diabetes mellitus. J Pharm Pract 2019; 32(4): 422-427.
24. Esubalew H, Belachew A, Seid Y, Wondmagegn H, Temesgen K, Ayele T. Health-related quality of life among type 2 diabetes mellitus patients using the 36-Item Short form health survey (SF-36) in central Ethiopia: A multicenter study. Diabetes Metab Syndr Obes 2024; 17: 1039-1049.
25. Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: The look ahead trial. Diabetes Care 2014; 37(6): 1544-1553.
26. Kolotkin RL, Jeppesen OK, Baker‐Knight J, Lee SY, Tokita A, Kadowaki T. Effect of once‐weekly subcutaneous semaglutide 2.4mg on weight‐ and health‐related quality of life in an East Asian popu-lation: Patient‐reported outcomes from the step 6 trial. Clinical Obesity 2023; 13(4): e12589.
27. Bjorner JB, Larsen S, Lübker C, Holst‐Hansen T. The improved health utility of once‐weekly subcu-taneous semaglutide 2.4 mg compared with placebo in the step 1‐4 obesity trials. Diabetes Obes Metab 2023; 25(8): 2142-2150.
28. Jódar E, Michelsen M, Polonsky W et al Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6). Diabetes Obes Metab 2020; 22: 1339-1347.
29. Volčanšek Š, Lunder M, Janež A. Health-related quality of life assessment in older patients with type 1 and type 2 diabetes. Healthcare 2023; 11(15): 2154.
30. Kuznetsov L, et al Diabetes-specific quality of life but not health status is independently associated with glycaemic control among patients with type 2 diabetes: A cross-sectional analysis of the ADDITION-Europe trial cohort. Diabetes Res Clin Pract 2014; 104: 281-287.
31. Engström MS, et al Health-related quality of life and glycaemic control among adults with type 1 and type 2 diabetes—a nationwide cross-sectional study. Health Qual Life Outcomes 2019; 17: 1-11.
32. Kintzoglanakis K, Pavlou-Skantzis L, Themeli T, Kyprianou M, Paschou SA. Determinants of health-related quality of life of patients with type 2 diabetes and multimorbidity: A cross-sectional study. Hormones 2024/ doi: 10.1007/s42000-024-00545-y.
33. Pati S, et al Impact of comorbidity on health-related quality of life among type 2 diabetic patients in primary care. Prim Health Care Res Dev 2021; 21(e9): 1-8.
34. Sajjadi SS, Bagherniya M, Soleimani D, et al Effect of propolis on mood, quality of life, and metabolic profiles in subjects with metabolic syndrome: a randomized clinical trial. Sci Rep 2023; 13: 4452.
35. Chen S, Chen S, Lai Y, et al Abdominal obesity and hypertension are correlated with health-related quality of life in Taiwanese adults with metabolic syndrome. BMJ Open Diabetes Res Care 2020; 8: e000947.
36. Makovski TT, Schmitz S, Zeegers MP, Stranges S, van den Akker M. Multimorbidity and quality of life: Systematic Literature Review and meta-analysis. Ageing Res Rev 2019; 53:100903.
37. Verhulst M, Teeuw W, Gerdes V, Loos B. Self-reported oral health and quality of life in patients with type 2 diabetes mellitus in primary care: A multi-center cross-sectional study. Diabetes Metab Syndr Obes 2019; 12: 883-899.
38. Edelmann F, et al Impaired physical quality of life in patients with diastolic dysfunction associates more strongly with neurohumoral activation than with echocardiographic parameters: Quality of life in diastolic dysfunction. Am Heart J 2011; 161(4): 797-804.
39. Vergara M, Östgren CJ, Nyström FH, Israelsson H. Sense of vitality is associated with cardiovascular events in type 2 diabetes independently of traditional risk factors and arterial stiffness. Diabet Med 2022; 40(2): e14938.
40. Grigorescu ED. Implications of the incretin treatment on the subclinical inflammatory status and the cardiac function in patients diagnosed with type 2 diabetes [dissertation]. “Grigore T. Popa” University of Medicine and Pharmacy, Iași, Romania; 2021.
41. Sonaglioni A, Lonati C, Rigamonti E, et al CHA2DS2-VASc score stratifies mortality risk in heart failure patients aged 75 years and older with and without atrial fibrillation. Aging Clin Exp Res 2022; 34: 1707-1720.
42. Harb SC, Wang TK, Nemer D, et al. CHA2DS2-VASc score stratifies mortality risk in patients with and without atrial fibrillation. Open Heart 2021; 8(2): e001794
43. Tahir H, et al Use of CHA2DS2-VASc Score in Patients without Atrial Fibrillation: Review of Litera-ture. J Card Cardi Sur 2021; 1: 5.

Additional Files

Published

2024-09-18

Issue

Section

INTERNAL MEDICINE - PEDIATRICS